FIELD: medicine, pulmonology, allergology.
SUBSTANCE: the present innovation deals with treating asthma due to introducing parabrominephenacyl bromide (PBPB) at the dosages ranged 0.1-10 mg/kg body weight. Therapeutic course lasts about 1 wk. The innovation in question provides efficient therapy due to inhibiting phospholipase A2 with PBPB in the dosages and the mode mentioned.
EFFECT: higher efficiency of prophylaxis and therapy.
36 cl, 8 dwg, 8 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR ASTHMA PREVENTION OR TREATMENT CONTAINING MONOACETHYLDIACYL GLYCERINE COMPOUND AS ACTIVE INGREDIENT | 2014 |
|
RU2636615C2 |
| USE OF LGG FOR PREVENTION OR TREATMENT OF RESPIRATORY ALLERGIES | 2006 |
|
RU2435598C2 |
| METHODS FOR DIAGNOSING AND TREATING RELATED TO TH2 INHIBITION | 2011 |
|
RU2578468C2 |
| COMPOSITION CONTAINING EXTRACT OR FRACTION FROM JUSTICIA PLANT | 2015 |
|
RU2671501C1 |
| DIAGNOSTICS AND TREATMENT METHODS ASSOCIATED WITH TH2 INHIBITION | 2011 |
|
RU2737245C2 |
| METHOD FOR ALLERGIC BRONCHIAL ASTHMA TREATMENT, BASED ON CYTOKINES IL-4 AND IL-13 GENES EXPRESSION INHIBITION USING SIRNA MOLECULES | 2016 |
|
RU2615463C1 |
| METHODS FOR TREATMENT OR PREVENTION OF ASTHMA BY ADMINISTERING IL-4R ANTAGONIST | 2013 |
|
RU2690675C2 |
| METHODS OF TREATING OR PREVENTING ASTHMA BY ADMINISTERING IL-4R ANTAGONIST | 2020 |
|
RU2832774C2 |
| COMBINATION OF CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROIDS, PHARMACEUTICAL FORMULATION AND USE THEREOF | 2021 |
|
RU2832340C1 |
| ANTIBODIES TO CD6 FOR THE TREATMENT OF SEVERE ASTHMA | 2019 |
|
RU2796586C2 |
